A three-dimensional cell spheroid model simulating the lung immune microenvironment, its construction method and application
By co-culturing epithelial cells, vascular endothelial cells, fibroblasts, and macrophages to construct a three-dimensional cell spheroid model with a particle size of 200-500 μm, the limitations of existing technologies in simulating the lung immune microenvironment are overcome, enabling more realistic lung disease research and drug evaluation.
Patent Information
- Application Number
- CN202510617366.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing three-dimensional cell culture technology has limitations in simulating the lung immune microenvironment. It cannot fully reflect multiple cell types and their interactions, and it is difficult to accurately reflect the real situation in vivo, thus failing to meet the needs of studying the mechanisms of lung diseases and evaluating drugs.
By co-culturing epithelial cells, vascular endothelial cells, fibroblasts and macrophages, a three-dimensional cell spheroid model with a particle size of 200-500 μm is formed. Optimized culture conditions and centrifugation techniques are used to ensure that the cell spheroids are uniform in size and have clear morphology, making them suitable for high-throughput screening applications.
This model can more realistically simulate the lung immune microenvironment, provide a physiologically relevant experimental platform, improve the reliability and reproducibility of experimental results, and is suitable for lung disease research and drug screening, significantly improving experimental efficiency.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the fields of bioculture technology and environmental toxicology technology, specifically to a three-dimensional cell spheroid model simulating the lung immune microenvironment, its construction method, and its application. Background Technology
[0002] As the body's primary respiratory organ, the lungs play a crucial role not only in gas exchange but also in protecting against pathogens, particulate matter, and airborne pollutants. The lung's immune microenvironment is highly complex, primarily composed of various cell types, including epithelial cells, immune cells (such as macrophages and lymphocytes), endothelial cells, and stromal cells. These cells are structurally and functionally interconnected, working together to maintain lung health and normal function. In recent years, with the development of biomedical research, researchers have increasingly focused on simulating this complex lung microenvironment in vitro to better study the mechanisms of lung disease development and the pulmonary toxicity mechanisms of pollutants. Currently, in vitro models used to study the pulmonary toxicity of pollutants mainly include two-dimensional planar cell line models, three-dimensional single-cell cultured cell spheroid models, and three-dimensional multi-cell cultured cell spheroids or organoid models.
[0003] Traditional two-dimensional cell culture methods involve culturing cells in a single layer in a cell culture dish, which cannot effectively simulate cell growth and interactions in three-dimensional space. Therefore, developing three-dimensional cell culture models has become an important research direction. Three-dimensional spheroids are an important method for simulating the three-dimensional growth environment of cells in vivo. Compared to two-dimensional culture, three-dimensional spheroids can better simulate the natural state of cells, especially in terms of intercellular interactions, signal transduction, and drug responses, showing significant advantages. Currently, three-dimensional spheroids are widely used in simulating the tumor microenvironment, studying tumor cell invasion and metastasis, and evaluating the efficacy of anticancer drugs.
[0004] However, while existing three-dimensional cell culture techniques have made significant progress in some aspects, they still have limitations in constructing complex models of the lung immune microenvironment, specifically: 1) Cell type diversity: Most existing models focus on culturing single or a few cell types, failing to comprehensively reflect the diverse cell types in the lung and their interactions. 2) Intercellular interactions: Traditional three-dimensional models have limitations in simulating complex intercellular interactions and signal transduction. 3) Simulation of the immune microenvironment: Current technologies are still insufficient in simulating the lung-specific immune microenvironment, making it difficult to accurately reflect the real situation in vivo. Therefore, there is an urgent need to develop a three-dimensional cell spherical model that can more comprehensively and realistically simulate the lung immune microenvironment. This model should include multiple lung cell types, reproduce complex intercellular interactions, and reflect the pathological and physiological states in vivo, in order to better study the mechanisms of lung diseases, evaluate drug efficacy, and provide a reliable in vitro experimental platform for related biomedical research. Summary of the Invention
[0005] The purpose of this invention is to provide a three-dimensional cell spheroid model that can more comprehensively and realistically simulate the lung immune microenvironment and its applications.
[0006] To achieve the above objectives, the present invention first provides a method for constructing three-dimensional cell spheres.
[0007] The method for constructing three-dimensional cell spheres provided by the present invention includes the following steps: co-culturing epithelial cells, vascular endothelial cells, fibroblasts and macrophages to form three-dimensional cell spheres that can simulate the immune microenvironment of the lungs.
[0008] In the above method, the particle size of the three-dimensional cell spheres is 200-500 μm.
[0009] In some embodiments, the particle size of the three-dimensional cell spheres is 244 μm.
[0010] In some embodiments, the particle size of the three-dimensional cell spheres is 307 μm.
[0011] In some embodiments, the particle size of the three-dimensional cell spheres is 389 μm.
[0012] In some embodiments, the particle size of the three-dimensional cell spheres is 509 μm.
[0013] In the above method, the epithelial cells may be lung epithelial cells; the lung epithelial cells include, but are not limited to, bronchial epithelial cells (such as human bronchial epithelial cells BEAS-2B), airway epithelial cells (such as airway epithelial cells HBE), alveolar basal epithelial cells (such as human alveolar basal epithelial cells A549), and alveolar epithelial cells (such as human alveolar epithelial cells HPAEPIC).
[0014] In some implementations, the epithelial cells are bronchial epithelial cells, specifically human bronchial epithelial cells BEAS-2B.
[0015] In the above method, the vascular endothelial cells may be venous vascular endothelial cells; the venous vascular endothelial cells include, but are not limited to, umbilical vein vascular endothelial cells (such as human umbilical vein vascular endothelial cells HUVEC).
[0016] In some implementations, the vascular endothelial cells are umbilical vein endothelial cells, specifically human umbilical vein endothelial cells (HUVECs).
[0017] In the above method, the fibroblasts may be lung fibrotic cells; the lung fibrotic cells include, but are not limited to, embryonic lung fibroblasts (such as human embryonic lung fibroblasts HFL1 and human embryonic lung fibroblasts MRC-5).
[0018] In some embodiments, the fibroblasts are embryonic lung fibroblasts, specifically human embryonic lung fibroblasts (HFL1).
[0019] In the above method, the macrophages are M0 macrophages obtained by inducing differentiation of peripheral blood mononuclear cells.
[0020] The peripheral blood mononuclear cells include, but are not limited to, human peripheral blood mononuclear cells (such as human peripheral blood mononuclear cells THP-1).
[0021] In some implementations, the peripheral blood mononuclear cells are human peripheral blood mononuclear cells, specifically human peripheral blood mononuclear cells THP-1.
[0022] In some embodiments, the macrophages are M0 macrophages (adhesive M0 macrophages) obtained by inducing differentiation of human peripheral blood mononuclear cells THP-1 with phorbol-12-myristate-13-acetate (PMA).
[0023] In some preferred embodiments, the method for inducing differentiation of human peripheral blood mononuclear cells THP-1 into M0 macrophages by PMA includes the following steps: when the human peripheral blood mononuclear cells THP-1 grow to the logarithmic growth phase, the cell density is adjusted to 5 × 10⁻⁶ cells / year. 5The concentration of PMA was increased to 100 ng / mL, and then PMA was added to the THP-1 cell suspension to achieve a final concentration of 100 ng / mL, thus obtaining a THP-1 cell suspension containing PMA. The THP-1 cell suspension containing PMA was then incubated in a 37°C, 5% CO2 incubator for 48 hours to obtain M0 macrophages.
[0024] The above method may include the following steps: mixing equal amounts of epithelial cells, vascular endothelial cells, fibroblasts and macrophages and placing them in a cell culture plate, centrifuging to allow the cells to rapidly aggregate and then culturing; the number of cells per well in the cell culture plate is 2500-20000.
[0025] Furthermore, the epithelial cells are an epithelial cell suspension; the epithelial cell suspension is a suspension obtained by mixing the mixed culture medium with the epithelial cells.
[0026] The vascular endothelial cells are a suspension of vascular endothelial cells; the vascular endothelial cell suspension is a suspension obtained by mixing the mixed culture medium with the vascular endothelial cells.
[0027] The fibroblasts are a suspension of fibroblasts; the suspension of fibroblasts is a suspension obtained by mixing the mixed culture medium with the fibroblasts.
[0028] The macrophages are macrophage suspensions; the macrophage suspensions are obtained by mixing the mixed culture medium with the macrophages.
[0029] The mixed culture medium is a culture medium obtained by mixing equal volumes of epithelial cell culture medium, vascular endothelial cell culture medium, fibroblast culture medium and peripheral blood mononuclear cell culture medium.
[0030] The epithelial cell culture medium is a medium obtained by mixing fetal bovine serum, penicillin-streptomycin, and DMEM medium. The volume fraction of fetal bovine serum in the epithelial cell culture medium is preferably 10%, and the volume fraction of penicillin-streptomycin in the epithelial cell culture medium is preferably 1%.
[0031] The vascular endothelial cell culture medium is a culture medium obtained by mixing fetal bovine serum, penicillin-streptomycin, endothelial cell culture additive, and endothelial cell-specific culture medium. Preferably, the volume fraction of fetal bovine serum in the vascular endothelial cell culture medium is 5%, the volume fraction of penicillin-streptomycin in the vascular endothelial cell culture medium is 1%, and the volume fraction of the endothelial cell culture additive in the vascular endothelial cell culture medium is 1%.
[0032] The fibroblast culture medium is a mixture of fetal bovine serum, L-alanyl-L-glutamine dipeptide, non-essential amino acids, penicillin-streptomycin, and F-12K medium. Preferably, the volume fraction of the fetal bovine serum in the fibroblast culture medium is 10%, the volume fraction of the L-alanyl-L-glutamine dipeptide is 1%, the volume fraction of the non-essential amino acids is 1%, and the volume fraction of the penicillin-streptomycin is 1%.
[0033] The peripheral blood mononuclear cell culture medium is a culture medium obtained by mixing fetal bovine serum with 1640 culture medium. The volume fraction of fetal bovine serum in the peripheral blood mononuclear cell culture medium is preferably 10%.
[0034] Furthermore, the number of cells in the epithelial cell suspension, the vascular endothelial cell suspension, the fibroblast suspension, and the macrophage suspension are the same.
[0035] The step of mixing equal amounts of epithelial cells, vascular endothelial cells, fibroblasts, and macrophages involves mixing equal volumes of the epithelial cell suspension, the vascular endothelial cell suspension, the fibroblast suspension, and the macrophage suspension.
[0036] The concentrations of the epithelial cell suspension, the vascular endothelial cell suspension, the fibroblast suspension, and the macrophage suspension are all (1-2)×10⁻⁶. 5 Cells / mL.
[0037] In some embodiments, the concentrations of the epithelial cell suspension, the vascular endothelial cell suspension, the fibroblast suspension, and the macrophage suspension are all 1×10⁻⁶. 5 Cells / mL.
[0038] Furthermore, the centrifugation conditions can be 100-300 g for 2-5 min, preferably 250 g for 3 min.
[0039] The culture conditions can be 37℃, 5% CO2, for 2-5 days.
[0040] The culture medium is changed every 2-3 days during the culture process.
[0041] In the above method, the cell culture plate is an ultra-low adsorption U-shaped bottom 96-well culture plate. The number of cells per well in the cell culture plate can be 2500, 5000, 10000, or 20000. The cell number refers to the total number of epithelial cells, vascular endothelial cells, fibroblasts, and macrophages.
[0042] In the above method, the cells are further cultured and expanded before mixing.
[0043] The epithelial cells were cultured and expanded using the aforementioned epithelial cell culture medium.
[0044] The vascular endothelial cells were cultured and expanded using the aforementioned vascular endothelial cell culture medium.
[0045] The fibroblasts were cultured and expanded using the aforementioned fibroblast culture medium.
[0046] The peripheral blood mononuclear cells were cultured and expanded using the aforementioned peripheral blood mononuclear cell culture medium.
[0047] In some implementations, the culture and amplification method may include the following steps: 1) Remove the frozen cell tubes from liquid nitrogen and quickly place them in a 37°C water bath to thaw until the cells are completely thawed; 2) Quickly transfer the thawed cells to a centrifuge tube, add 10 times the volume of suitable culture medium, centrifuge at 1000 rpm for 3 min, and discard the supernatant; 3) Resuspend the cell pellet in fresh, suitable culture medium and transfer it to a culture flask for incubation at 37°C in a 5% CO2 incubator; 4) When the cell density reaches 70%-80% confluence, perform subculture.
[0048] In step 4) above, the epithelial cells are passaged at a ratio of 1:6, and the vascular endothelial cells, fibroblasts and peripheral blood mononuclear cells are passaged at a ratio of 1:2.
[0049] Following step 4) above, the following steps are also included: digesting cells with trypsin (e.g., 0.25% trypsin-EDTA) and adjusting the concentration of the cell suspension using the above-mentioned mixed culture medium. Specifically, the following steps are included: removing the old culture medium from epithelial cells, vascular endothelial cells, fibroblasts, and macrophages, and gently washing the cells 1-2 times with PBS buffer; adding trypsin to digest the cells until the cells detach from the flask wall, adding preheated suitable culture medium to neutralize the trypsin, and gently pipetting to completely suspend the cells; transferring the digested cell suspension to centrifuge tubes, centrifuging at 1000 rpm for 3 min, and discarding the supernatant; resuspending the cells in the mixed culture medium, and taking a certain volume of the cell suspension for counting using a cell counter; adjusting the concentration of the cell suspension to (1-2) × 10⁻⁶ cells based on the counting results. 5 Cells / mL.
[0050] The three-dimensional cell spheres constructed according to the above method are also within the scope of protection of this invention.
[0051] To achieve the above objectives, the present invention further provides a composition for constructing three-dimensional cell spheres.
[0052] The composition provided by the present invention includes the above-mentioned epithelial cells, vascular endothelial cells, fibroblasts and peripheral blood mononuclear cells.
[0053] Furthermore, the composition may also include the above-mentioned epithelial cell culture medium, the above-mentioned vascular endothelial cell culture medium, the above-mentioned fibroblast culture medium, and the above-mentioned peripheral blood mononuclear cell culture medium.
[0054] Furthermore, the composition may also include phorbol-12-myristoyl-13-acetate.
[0055] Furthermore, the composition may also include trypsin (such as 0.25% trypsin-EDTA) and PBS buffer pH 7.2.
[0056] To achieve the above objectives, the present invention also provides applications in any of the following 1)-9): 1) Application of the above-mentioned method for constructing three-dimensional cell spheres in the detection of pollutant pulmonary toxicity; 2) Application of the above-mentioned method for constructing three-dimensional cell spheres in the study of the lung toxicity mechanism of pollutants; 3) The application of the above-mentioned method for constructing three-dimensional cell spheres in screening or developing drugs for the treatment of lung diseases; 4) Application of the above-mentioned method for constructing three-dimensional cell spheres in the study of the pathogenesis and / or progression of lung diseases; 5) The application of the three-dimensional cell spheres constructed according to the above method or the above composition in the detection of lung toxicity of pollutants or in the preparation of products for the detection of lung toxicity of pollutants; 6) The application of the three-dimensional cell spheres constructed according to the above method or the above composition in studying the lung toxicity mechanism of pollutants or in preparing products for studying the lung toxicity mechanism of pollutants; 7) The use of the three-dimensional cell spheres constructed according to the above method or the above composition in screening or developing drugs for the treatment of lung diseases or in preparing products for screening or developing drugs for the treatment of lung diseases; 8) The use of the three-dimensional cell spheres constructed according to the above method or the above composition in the study of the pathogenesis and / or disease progression of lung diseases or in the preparation of products for the study of the pathogenesis and / or disease progression of lung diseases; 9) Use of the above composition in constructing three-dimensional cell spheres or in preparing products that construct three-dimensional cell spheres.
[0057] To achieve the above objectives, the present invention finally provides a method for detecting the lung toxicity of pollutants.
[0058] The method for detecting the lung toxicity of pollutants provided by the present invention includes the step of treating three-dimensional cell spheres constructed according to the above-described method with pollutants.
[0059] Furthermore, the pollutants include, but are not limited to, quaternary ammonium salts, polycyclic aromatic hydrocarbons, organophosphates, bactericides, plasticizers, heavy metals, and particulate matter.
[0060] In some embodiments, the quaternary ammonium salt contaminant is octadecyl dimethyl benzyl ammonium chloride, N,N,N-trimethyl-1-tetradecyl ammonium bromide, or N,N-dimethyl-N-octyl-1-decyl ammonium chloride.
[0061] Furthermore, the treatment method may include the following steps: adding a contaminant to the three-dimensional cell sphere solution constructed above, and assessing the pulmonary toxicity of the contaminant by observing and recording morphological changes and / or activity changes of the three-dimensional cell spheres.
[0062] The concentration of the contaminant in the three-dimensional cell sphere solution can be 10-40 µM.
[0063] In some embodiments, the concentration of the contaminant in the three-dimensional cell sphere solution is 10 µM, 20 µM, or 40 µM.
[0064] This invention provides an efficient and convenient method for constructing a three-dimensional cell spheroid model. This method involves co-culturing epithelial cells, vascular endothelial cells, fibroblasts, and macrophages to form a three-dimensional cell spheroid model that simulates the lung's immune microenvironment. Furthermore, optimized culture conditions and centrifugation techniques ensure that the three-dimensional cell spheroids are uniform in size and have clear edges, making them suitable for high-throughput screening applications. The three-dimensional cell spheroid model prepared by this invention can more realistically simulate the lung's immune microenvironment, providing more physiologically relevant experimental results; it also allows for the co-growth of multiple lung cell types, facilitating the study of intercellular interactions and signal transduction. This invention provides an important tool and strong technical support for studying the pathogenesis, pathological processes, drug mechanisms of action, and clinical applications of lung diseases, and has broad application prospects in lung disease research, drug screening, and the analysis and detection of toxicity from pollutant exposure to the lungs.
[0065] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention successfully constructs a three-dimensional cell spheroid model containing multiple lung cell types by co-culturing epithelial cells, vascular endothelial cells, fibroblasts, and macrophages. This model can comprehensively simulate the cellular heterogeneity and complexity of the lung microenvironment, providing a more realistic in vitro platform for studying intercellular interactions. Compared with traditional two-dimensional culture models, the three-dimensional cell spheroid model of this invention can better simulate the three-dimensional growth environment of cells in vivo, preserving the natural morphology and function of cells. This three-dimensional structure can more realistically reflect the physiological characteristics of lung cells under normal and pathological conditions, improving the physiological relevance of experimental results.
[0066] 2. The three-dimensional cell spheroid model constructed in this invention can effectively simulate the complex interactions and signal transduction between different cell types, including the interactions between epithelial cells and immune cells, and between endothelial cells and fibroblasts. This is helpful for in-depth research on the pathogenesis of lung diseases and the role of intercellular interactions in disease progression. Furthermore, by introducing macrophages, the three-dimensional cell spheroid model of this invention can better simulate the lung-specific immune microenvironment, including processes such as immune cell activation, migration, and inflammatory responses. This model provides a dynamic and controllable in vitro system for studying lung immune responses and pollutant toxicity mechanisms.
[0067] 3. This invention provides a standardized preparation method and optimized culture conditions for three-dimensional cell spheroid models, making the preparation process simple and efficient, reducing operational steps and time costs. Through optimized culture techniques, the three-dimensional cell spheroid models of this invention exhibit uniform size and morphology, contributing to improved reproducibility and reliability of experimental data. Furthermore, due to the simple preparation process and uniform size of the three-dimensional cell spheroid models, they are highly suitable for high-throughput screening applications. These models can be cultured and processed in multi-well plates, facilitating large-scale screening experiments such as drug screening and toxicity testing, significantly improving experimental efficiency and data processing capabilities. This provides an efficient and reliable experimental platform for developing new drugs and studying the health effects of environmental pollutants.
[0068] In summary, the three-dimensional cell spheroid model of this invention has significant advantages in simulating the lung immune microenvironment, including multi-cell co-culture, more realistic physiological relevance, simulation of intercellular interactions, dynamic immune microenvironment simulation, simple culture, uniform size, ease of high-throughput screening, and broad application prospects. These advantages provide a powerful tool for studying lung diseases and toxicity mechanisms, promoting research progress and application development in related fields. Attached Figure Description
[0069] Figure 1 This is a flowchart illustrating the construction process of the three-dimensional cell spheres of the present invention.
[0070] Figure 2 The image shows the morphology of cell spheres formed after culturing different cell numbers for 48 hours in an embodiment of the present invention. The scale bar is 100 μm.
[0071] Figure 3 These are morphological images of live and dead cells stained and Hochest stained in embodiments of the present invention. Blue represents the cell nucleus; green represents live cells; and red represents dead cells.
[0072] Figure 4 This is a diagram showing the morphological differences between the experimental group and the control group of spherical bodies in an embodiment of the present invention.
[0073] Figure 5 The difference in diameter between the experimental group and the control group in this embodiment of the invention is shown.
[0074] Figure 6 The changes in the viability of globular cells in the experimental group and the control group in this embodiment of the invention are shown. Detailed Implementation
[0075] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.
[0076] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.
[0077] The human bronchial epithelial cells BEAS-2B used in the following examples are products of Hunan Fenghui Biotechnology Co., Ltd., with catalog number CL0044.
[0078] The human umbilical vein endothelial cells (HUVECs) used in the following examples are products of Hunan Fenghui Biotechnology Co., Ltd., with catalog number CL0170.
[0079] The human embryonic lung fibroblasts HFL1 in the following examples are Pronossa products, catalog number CL-0106.
[0080] The human peripheral blood mononuclear cells THP-1 used in the following examples are Pronossa products, catalog number CL-0233.
[0081] The octadecyl dimethyl benzyl ammonium chloride used in the following examples is a product of MCE, with catalog number HY-128443 and CAS number 122-19-0.
[0082] The N,N,N-trimethyl-1-tetradecylammonium bromide used in the following examples is a product of MCE, catalog number HY-D0839, CAS number 1119-97-7.
[0083] The N,N-dimethyl-N-octyl-1-decammonium chloride used in the following examples is a product of Shanghai BIDE Pharmaceutical Technology Co., Ltd., with product number BD00945610 and CAS number 32426-11-2.
[0084] Example 1: A method for constructing a three-dimensional cell spheroid model simulating the lung immune microenvironment. The flowchart of the construction process of the three-dimensional cell sphere model of this invention is as follows: Figure 1 As shown. The specific steps are as follows: I. Planar culture of lung epithelial cells, endothelial cells, fibroblasts and monocytes 1. Cell resuscitation Human bronchial epithelial cells BEAS-2B, human umbilical vein endothelial cells HUVEC, human embryonic lung fibroblasts HFL1, and human peripheral blood mononuclear cells THP-1 were revived from liquid nitrogen. The specific steps are as follows: Remove the frozen cell tubes from the liquid nitrogen and quickly place them in a 37°C water bath to thaw. Gently shake the cell tubes during thawing to ensure even heating of the cells until they are completely thawed (approximately 1-2 minutes).
[0085] 2. Cell culture after resuscitation The revived cells were seeded into a suitable complete culture medium and cultured and expanded in a 37°C, 5% CO2 incubator until the cells reached a suitable number. The specific steps are as follows (the complete culture medium mentioned below refers to a suitable medium for each cell type): 1) Quickly transfer the thawed cell suspension to a centrifuge tube, add 10 times the volume of preheated complete culture medium, centrifuge at 1000 rpm for 5 min, and discard the supernatant.
[0086] 2) Resuspend the cell pellet in fresh complete culture medium and transfer it to a culture flask. Incubate the cells at 37°C in a 5% CO2 incubator. Observe the cell growth status daily and change the culture medium as needed.
[0087] 3) When the cell density reaches 70%-80% confluence, perform subculture. BEAS-2B cells are subcultured at a ratio of 1:6, and other cell types are subcultured at a ratio of 1:2. The specific steps for subculture are as follows: Remove the old culture medium and gently wash the cells 1-2 times with PBS buffer (Gibco, 20012027, pH 7.2). Then add 1 mL of 0.25% trypsin-EDTA (Gibco) and digest the cells at room temperature for 2 min. Add complete culture medium to neutralize the trypsin, and gently pipette to completely suspend the cells. Finally, centrifuge at 1000 rpm for 3 min, discard the supernatant, and resuspend the cell pellet in fresh culture medium.
[0088] The suitable culture medium formulations for each cell type are as follows: BEAS-2B cell culture medium (epithelial cell culture medium): 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin were added to DMEM medium (Gibco, catalog number 11995073).
[0089] HUVEC cell culture medium (vascular endothelial cell culture medium): Add 5% (volume fraction) fetal bovine serum, 1% (volume fraction) endothelial cell culture additive and 1% (volume fraction) penicillin-streptomycin to endothelial cell-specific culture medium (Pronosai, catalog number CM-0122).
[0090] HFL1 cell culture medium (fibroblast culture medium): 10% (v / v) fetal bovine serum, 1% (v / v) non-essential amino acids (Gibco, 11140050) and 1% (v / v) penicillin-streptomycin were added to F-12K medium (Gibco, catalog number 21127022).
[0091] THP-1 cell culture medium (peripheral blood mononuclear cell culture medium): 10% (volume fraction) fetal bovine serum was added to 1640 medium (Gibco, catalog number 8117072).
[0092] II. Obtaining M0 macrophages When THP-1 cells reached the logarithmic growth phase, the cell density was adjusted to 5 × 10⁻⁶. 5 A phorbol-12-myristate-13-acetate (PMA) solution was prepared using DMSO. The PMA solution was then added to the THP-1 cell suspension to achieve a final PMA concentration of 100 ng / mL, resulting in a THP-1 cell suspension containing PMA. The PMA-containing THP-1 cell suspension was aliquoted into six-well plates, with 2 mL added to each well. The plates were incubated at 37°C in a 5% CO2 incubator for 48 hours to induce THP-1 cells to differentiate into adhesive M0 macrophages.
[0093] III. Culture of a Three-Dimensional Cell Spheroid Model 1. Cellular digestion The four cell types (BEAS-2B, HUVEC, HFL1, and adhesive M0 macrophages) were digested with trypsin and counted to achieve the same density. The specific steps are as follows: Remove the old culture medium from the BEAS-2B, HUVEC, HFL1, and adhesive M0 macrophages, and gently wash the cells 1-2 times with PBS buffer; add an appropriate amount of 0.25% trypsin-EDTA to digest the cells at room temperature until they detach from the flask wall; add preheated complete culture medium to neutralize the trypsin, and gently pipette to completely suspend the cells; transfer the digested cell suspension to centrifuge tubes, centrifuge at 1000 rpm for 3 min, and discard the supernatant; resuspend the cells with an appropriate amount of mixed culture medium, and take a certain volume of the cell suspension for counting using a cell counter; based on the counting results, adjust the concentration of the BEAS-2B, HUVEC, HFL1, and M0 macrophage suspensions to (1-2) × 10⁻⁶. 5 Cells / mL.
[0094] The mixed culture medium is a culture medium obtained by mixing the culture media of the above four types of cells (epithelial cell culture medium, vascular endothelial cell culture medium, fibroblast culture medium, and peripheral blood mononuclear cell culture medium) in a volume ratio of 1:1:1:1.
[0095] 2. Cell mixing BEAS-2B cell suspension, HUVEC cell suspension, HFL1 cell suspension, and M0 macrophage cell suspension were mixed in a volume ratio of 1:1:1:1. The mixed cell suspension was then slowly dispensed into 96-well ultra-low adsorption U-bottom microsphere culture plates (Revity), ensuring that each well contained 2500-20000 cells (2500, 5000, 10000, and 20000). The process was carried out gently, avoiding touching the bottom of the wells with the pipette tip, and the volume was brought up to 100 μL / well using the mixed culture medium.
[0096] 3. Culture of mixed cells Cap the 96-well microsphere culture plate and place it in a plate centrifuge. Centrifuge at 250 g (RCF) for 2 min to allow the cells to quickly aggregate. Transfer the culture plate to a CO2 incubator and incubate at 37°C with 5% CO2. Change the culture medium every 2-3 days to ensure the cells grow in a favorable environment.
[0097] 4. Microscopic observation of cell spheroid formation During the culture process, the formed cell spheres are observed under a microscope. After 2-5 days, the cells automatically aggregate into three-dimensional cell spheres with a three-dimensional structure and clear edges.
[0098] Example 2: Characterization of a three-dimensional cell spheroid model I. Measurement of the diameter of three-dimensional cell spheroids To ensure the quality of the 3D cell spheroid model, the formation of cell spheroids with different cell numbers was observed under a microscope, and the diameter of the cell spheroids was measured using ImageJ software. Following the method in Example 1, cell spheroids with 2500, 5000, 10000, and 20000 cells / well were cultured, with the four cell counts mixed in a 1:1:1:1 ratio. After 48 hours of cell spheroid culture, the formation of cell spheroids in each well was observed using an inverted microscope. Three to five representative cell spheroids were selected and photographed to ensure clear images, which were then analyzed. The specific analysis method is as follows: The cell spheroid images taken under the microscope were imported into ImageJ software. The length of the scale was measured using ImageJ's line tool, and 'Analyze>Set Scale' was selected in the menu. The actual length and unit of the scale were entered, and the image scale was calibrated. The edges of the cell spheroids were outlined using the Oval Tool or the Freehand Tool, and 'Analyze>Measure' was selected in the menu. ImageJ automatically calculated and displayed the diameter of the cell spheroids. Calculate the mean and standard deviation of cell sphere diameter for each cell number setting, analyze the differences in cell sphere diameter formed by different numbers of cells, and assess the uniformity of cell sphere size.
[0099] Cell spheroid images and diameter measurement results are as follows: Figure 2 As shown, the results indicate that the obtained cell spheres had diameters between 200 and 500 μm, exhibited stable morphology, and were uniform in size. Specifically, the cell sphere diameter was 244 μm when the cell count was 2500 per well, 307 μm when the cell count was 5000 per well, 389 μm when the cell count was 10000 per well, and 509 μm when the cell count was 20000 per well.
[0100] II. Detection of cell viability in three-dimensional cell spheres To determine the cell viability in the cultured cell spheres, LIVE / DEAD cell viability assays were performed on cell spheres formed with different numbers of cells from Example 1. The specific steps are as follows: 1. Preparation of dye working solution Prepare the working solution for the LIVE / DEAD Cell Viability Assay Kit (Thermo Fisher Scientific, L3224) according to the instructions. This solution includes two dyes: Calcein-AM and Propidium Iodide (PI). Calcein-AM is used to stain live cells, displaying green fluorescence; PI is used to stain dead cells, displaying red fluorescence.
[0101] 2. Staining Remove an appropriate amount of cell spheres from the culture plate and transfer them to a new centrifuge tube using a pipette. Discard the culture medium and wash twice with PBS. Add 1 μM of LIVE / DEAD dye working solution to the centrifuge tube, ensuring the dye fully covers the cell spheres. Incubate the stained cell spheres at 37°C in the dark for 2 hours to ensure the dye fully penetrates and binds to the cells. After staining, gently centrifuge to collect the cell spheres and discard the dye supernatant. Gently wash the cell spheres 1-2 times with PBS buffer to remove unbound dye. Then add Hochest staining reagent (Thermo Fisher Scientific, R37165) to stain the cell nuclei and continue incubation in the dark for 2 hours.
[0102] 3. Observe after staining The stained cell spheres were transferred to a confocal dish and observed under a confocal microscope in the green and red channels to record the fluorescence signals of live and dead cells. The staining of the cell nuclei was observed in the blue channel to assess the viability of the cell spheres.
[0103] The results are as follows Figure 3 As shown in the figure. The results showed that the four cell types spontaneously formed cell spheroids with regular edges and tight structure, and the cell spheroids had good viability with very few dead cells.
[0104] Example 3: Effects of environmental pollutants on lung cell morphology and cell viability Different concentrations of the compound were added to the three-dimensional cell sphere model constructed in Example 1. The toxicity of the compound to lung cell spheres was evaluated by observing and recording the growth and morphological changes of the cell spheres and detecting cell activity.
[0105] 1. Formation of three-dimensional cell spheres Following the method described in Example 1, BEAS-2B, HUVEC, HFL1, and THP-1 cells were cultured, counted, and adjusted to a concentration of 1 × 10⁻⁶ cells. 5 Cells / mL were mixed in a volume ratio of 1:1:1:1. The mixed cell suspension was then seeded into 96-well plates with an ultra-low adsorption U-shaped bottom, with 100 μL added to each well, resulting in 10,000 cells per well. After 2 days of culture, the cells formed three-dimensional cell spheroids.
[0106] 2. Exposure to environmental pollutants Several quaternary ammonium salts (octadecyl dimethyl benzyl ammonium chloride, N,N,N-trimethyl-1-tetradecyl ammonium bromide, and N,N-dimethyl-N-octyl-1-decyl ammonium chloride) were selected as common environmental pollutants, and each compound was dissolved in DMSO to prepare 100 mM stock solutions.
[0107] The resulting three-dimensional cell spheres were divided into multiple experimental groups, each exposed to different concentrations of quaternary ammonium salts (10 µM, 20 µM, and 40 µM), with DMSO as the control group. Each group was treated at 37°C and 5% CO2 for 24 hours to assess the impact of pollutants on the three-dimensional cell spheres.
[0108] 3. Changes in cell spheroid morphology After the compound treatment, the morphology of each group of cell spheres was observed and photographed using an inverted microscope. The diameter of the cell spheres was measured using ImageJ software to assess the impact of contaminants on the structural integrity of the cell spheres.
[0109] The results are as follows Figure 5 As shown, the results indicate that exposure to high concentrations of several quaternary ammonium salts to cell spheres leads to the shedding or even disintegration of the outer cell layer, resulting in an increase in cell sphere diameter.
[0110] 4. Detection of cell spheroid viability To further evaluate the effect of compound exposure on cell viability, the CellTiter-Glo (CTG) luminescent cell viability assay kit (Promega, G7570) was used to quantitatively detect the cell viability of three-dimensional cell spheroids in each group after compound treatment. The specific steps are as follows: 1) Prepare the luminescent detection working solution according to the CTG kit instructions. Dissolve the CellTiter-Glo substrate in an appropriate amount of CTG buffer, mix thoroughly, and store in the dark for later use.
[0111] 2) After the cell spheres are exposed, remove the culture medium from the culture plate and add 20 μL of CTG working solution to each well, ensuring that it fully covers the entire cell sphere.
[0112] 3) Place the culture plate in a shaker in the dark for 1 hour to ensure that the CTG working solution fully lyses the cell spheroids.
[0113] 4) After incubation, transfer the liquid in the culture plate to a 96-well white plate and use a fluorescence microplate reader to detect the light intensity of each well to reflect the metabolic activity and survival of the cells.
[0114] 5) Normalize the luminescence intensity data of each group of cell spheres and calculate the percentage of cell activity. The luminescence intensity of the control group is set to 100%, and the luminescence intensity of the treatment group is compared with that to obtain the percentage of cell activity. The impact of pollutants on the activity of three-dimensional cell spheres is assessed by the percentage of cell activity.
[0115] The results are as follows Figure 6 As shown, the results indicate that several quaternary ammonium compounds caused a significant decrease in the viability of three-dimensional spheroid cells after exposure, indicating that they are cytotoxic to the lungs.
[0116] The results indicate that quaternary ammonium disinfectants significantly affect the morphology and cell viability of a three-dimensional lung cell spheroid model. With increasing pollutant concentration, the morphology of the cell spheroids became abnormal, and cell viability decreased. This provides an effective in vitro model for further research on the toxic mechanisms of pollutants on the lungs and offers important data for evaluating the harm of environmental pollution to lung health.
[0117] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.
Claims
1. A method for constructing a three-dimensional cell sphere, the method comprising the following steps: co-culturing epithelial cells, vascular endothelial cells, fibroblasts and macrophages to form a three-dimensional cell sphere capable of mimicking the immune microenvironment of the lungs.
2. The method according to claim 1, characterized in that: The particle size of the three-dimensional cell spheres is 200-500 μm.
3. The method according to claim 1 or 2, characterized in that: The epithelial cells are bronchial epithelial cells of the lungs; Alternatively, the vascular endothelial cells may be umbilical vein endothelial cells; Alternatively, the fibroblasts may be embryonic lung fibroblasts; Alternatively, the macrophages may be M0 macrophages obtained by inducing differentiation of peripheral blood mononuclear cells.
4. The method according to any one of claims 1-3, characterized in that: The method includes the following steps: equal amounts of epithelial cells, vascular endothelial cells, fibroblasts and macrophages are mixed and placed in a cell culture plate, centrifuged to allow the cells to rapidly aggregate, and then co-cultured; the number of cells in each well of the cell culture plate is 2500-20000.
5. The method according to claim 4, characterized in that: The epithelial cells are an epithelial cell suspension; the epithelial cell suspension is a suspension obtained by mixing the mixed culture medium with the epithelial cells. Alternatively, the vascular endothelial cells are a suspension of vascular endothelial cells; the vascular endothelial cell suspension is a suspension obtained by mixing the mixed culture medium with the vascular endothelial cells. Alternatively, the fibroblasts are a fibroblast suspension; the fibroblast suspension is a suspension obtained by mixing the mixed culture medium with the fibroblasts. Alternatively, the macrophages are macrophage suspensions; the macrophage suspension is a suspension obtained by mixing the mixed culture medium with macrophages. Alternatively, the mixed culture medium is a culture medium obtained by mixing equal volumes of epithelial cell culture medium, vascular endothelial cell culture medium, fibroblast culture medium and peripheral blood mononuclear cell culture medium; Alternatively, the number of cells in the epithelial cell suspension, the vascular endothelial cell suspension, the fibroblast suspension, and the macrophage suspension is the same; Alternatively, the step of mixing equal amounts of epithelial cells, vascular endothelial cells, fibroblasts, and macrophages can be described as mixing equal volumes of the epithelial cell suspension, the vascular endothelial cell suspension, the fibroblast suspension, and the macrophage suspension.
6. The method according to claim 4 or 5, characterized in that: The centrifugation conditions are 100-300 g for 2-5 min; Alternatively, the culture conditions are 37°C and 5% CO2 for 2-5 days.
7. A three-dimensional cell sphere constructed according to any one of claims 1-6.
8. A composition for constructing a three-dimensional cellular sphere, said composition comprising epithelial cells, vascular endothelial cells, fibroblasts, and peripheral blood mononuclear cells.
9. Application of any one of the following: 1)-9) 1) The application of the method according to any one of claims 1-7 in the detection of pulmonary toxicity of pollutants; 2) The application of the method according to any one of claims 1-7 in the study of the pulmonary toxicity mechanism of pollutants; 3) The use of the method according to any one of claims 1-7 in screening or developing drugs for the treatment of lung diseases; 4) The application of the method described in any one of claims 1-7 in the study of the pathogenesis and / or progression of lung diseases; 5) The use of the three-dimensional cell spheres constructed according to any one of claims 1-6 or the composition of claim 8 in the detection of lung toxicity of pollutants or in the preparation of products for the detection of pollutant toxicity; 6) The use of the three-dimensional cell spheres constructed according to any one of claims 1-6 or the composition of claim 8 in studying the pulmonary toxicity mechanism of pollutants or in preparing products for studying the pulmonary toxicity mechanism of pollutants; 7) The use of the three-dimensional cell spheres constructed according to any one of claims 1-6 or the composition of claim 8 in screening or developing drugs for the treatment of lung diseases or in preparing products for screening or developing drugs for the treatment of lung diseases; 8) The use of the three-dimensional cell spheres constructed according to any one of claims 1-6 or the composition of claim 8 in the study of the pathogenesis and / or disease progression of lung diseases or in the preparation of products for the study of the pathogenesis and / or disease progression of lung diseases; 9) Use of the composition of claim 8 in constructing three-dimensional cell spheres or in preparing products that construct three-dimensional cell spheres.
10. A method for detecting the pulmonary toxicity of a pollutant, the method comprising the step of treating a three-dimensional cell sphere constructed according to any one of claims 1-6 with the pollutant.
